Podcasts about aetion

Send us a textIn this episode we interview Natalie Schibell, Market Strategist at Aetion and former Naval officer turned product marketing powerhouse.What you'll learn in this episode:How military discipline and empathy fuel Natalie's marketing approachThe three foundational pillars of successful product marketing: strategy, empathy, and executionWhy product marketers are often the most essential and overlooked voices in a companyHow to conduct meaningful product and competitor research—without a big budgetA step-by-step framework to transform research into a compelling narrativeThe role of AI in supercharging your content creation and productivityCommon pitfalls product marketers face and how to avoid them with clarity and precisionNatalie's journey from the CDC to Forrester and into tech leadership

In this episode of Real World Talk, host Sandy Leonard sits down with Ulka Campbell, Head of Scientific Strategy at Aetion, and CK Wang, Chief Medical Officer at COTA. They dive into the Aetion CARE program, a cross-industry initiative aimed at understanding real-world data's role in evaluating oncology therapeutics.Campbell explains the importance of the CARE program, emphasizing the collaborative approach involving various stakeholders. The team is working on emulating trials, focusing on study design, data fitness, and documenting learnings. The goal is to support oncology therapeutic development, approval, and access.Wang adds insights into the differentiation between EHR and claims data sources, highlighting the specific needs in oncology trials. The conversation concludes with a look into the future of oncology research, leaving listeners with a clear understanding of the CARE program's significance and its potential impact on the field.

Former FDA Commissioner Scott Gottlieb, MD returns to look at the systemic problems within the CDC and how we might fix them. He describes how the agency's bureaucratic glut, mission creep, and lack of transparency contributed to the disastrous COVID-19 response and America's loss of trust in its public health institutions. Later in the episode we turn focus to the FDA and reforming its approval process for innovative drugs and technologies, and end with a conversation about drug pricing reforms. Scott Gottlieb, MD, is the author of "Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic." He is a resident fellow at the American Enterprise Institute. From 2017 to 2019 he served as the 23rd commissioner of the Food and Drug Administration. Dr. Gottlieb is also a special partner with the venture capital firm New Enterprise Associates and serves on the boards of Pfizer, Illumina, Aetion, and Tempus. Follow him on Twitter at @ScottGottliebMD.

Hello my beautiful Woman Inc. Listeners! My guest this week is Cathy Polinsky, a seasoned technology executive with over 20 years of industry experience and happens to be a VP of Engineering at Shopify.  Cathy was most recently the Chief Technology Officer at Stitch Fix, an online personal shopping service. Cathy helped take Stitch Fix public and led the Engineering, Product and IT organizations through rapid growth.  Prior to Stitch Fix, Cathy led a variety of engineering organizations and initiatives at Salesforce for seven years, including her role as SVP of Engineering. She also built robust, large-scale systems and led engineering teams at top companies like Amazon, Yahoo! and Oracle.  She is currently an independent board director at Aetion and graduated from Swarthmore College with a special major in computer science and is a member of the Swarthmore College Board of Managers. I am a huge Shopify fan— which I probably mentioned a hundred times in this episode, but it the platform my team and I have used to build a multimillion dollar business and I was so excited to meet the woman who is engineering much of the tech that I get to use every day. Cathy is not only brilliant, but also incredibly down to earth and my favorite part was probably talking about her role as a mom.  I hope this conversation brings you the one little bit of inspiration that you need to hear. Now, let's get over to my conversation with Cathy.  

What about Omicron has most surprised the scientific community? What does it tell us about vaccines and where we're heading? These are among the big questions we have for Dr. Scott Gottlieb, former Commissioner of the FDA and author of The New York Times Bestseller: “Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic”. Scott currently serves on the boards of Pfizer, Illumina, Aetion, and Tempus. He is a special partner with the venture capital firm New Enterprise Associates, and a senior fellow at the American Enterprise Institute. You can order Scott Gottlieb's book here: https://www.barnesandnoble.com/w/uncontrolled-spread-scott-gottlieb/1139568341 And you can follow him on twitter here: @ScottGottliebMD

Former FDA Commissioner Scott Gottlieb, MD joins us to review the mistakes, misrepresentations, and institutional barriers at the CDC and other public health institutions that hindered our response to the COVID-19 pandemic - along with the tactical steps we must take to defeat the next pandemic. We also discuss reforming the FDA approval process to allow medical innovation and why the drug price controls found in the Democrats' HR3 legislation will stop the next breakthrough drugs from emerging. Scott Gottlieb, MD, is the author of "Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic." He is a resident fellow at the American Enterprise Institute. From 2017 to 2019 he served as the 23rd commissioner of the Food and Drug Administration. Dr. Gottlieb is also a special partner with the venture capital firm New Enterprise Associates and serves on the boards of Pfizer, Illumina, Aetion, and Tempus. Follow him on Twitter at @ScottGottliebMD.

Today on Health in 2 Point 00, the survey says digital health is optimistic! Find out more on the other side. On Episode 207, Jess asks Matthew about Aetion getting $110 million bringing its total to $212 million working on real world evidence for pharma companies, and Indonesian telehealth company Halodoc gets $80 million. MSK startup Vori Health gets $45 million—can they compete with Hinge? Next, Heartbeat Health gets $20 million for cardiovascular health. Finally, Andreesen throws $10.5 million in a Series A to Memora Health which is a patient messaging system. Don't forget to join us on Clubhouse tonight for more!

In this episode, Tonje talks to Ben Taylor, MSc PhD pharmacoepidemiologist and healthcare executive about how the last year has been for him both professionally and personally, about lessons in consequence, failure and success creativity and science, about systems and building teams and longing for the sparkle outside of it all. Ben is the Vice President at Aetion, Inc, a New-York-based health technology company. His work at Aetion has been instrumental in the fight against COVID19 since March, from understanding the effectiveness of early drug combinations in hospitalized patients, to now designing long-term safety studies in the US as vaccines roll out to our population.

In this episode, I chat with Divya Shanmugam, a Graduate Student in the Clinical and Applied Machine Learning Group at MIT CSAIL advised by Prof. John Guttag. Divya completed her undergrad from MIT itself and majored in computer science with a concentration in South Asian studies. She has also interned at Microsoft Research, Borealis AI, D.E. Shaw Research, Counsyl, and Aetion. Divya is currently focused on building machine learning models that are resilient to unreliable data. We talk about her growing up in a family of academics and getting an early initiation into the world of scientific research; delving into the intersection of computation and biology; differing experiences in an industrial and academic research setting; choosing a graduate school lab and project; virtual seminars and conferences; the importance of a humanistic perspective to contextualise advances in computing; diversity and its connection with ensembles; her current eclectic reading list; and many more things!!

In this episode of Her Story, we sat down with Carolyn Magill, CEO of Aetion. We discuss how Carolyn's accidental foray into healthcare, but intentional path to leadership, has shaped her wide-lens view of the industry.

Arundhati interviewed Carolyn Magill, CEO of Aetion. They discussed the growing importance of real-world evidence in getting drugs approved and reimbursed.   Episode Resources Connect with Arundhati Parmar aparmar@medcitynews.com  https://twitter.com/aparmarbb?lang=en https://medcitynews.com/ Connect with Carolyn Magill carolyn.magill@aetion.com https://www.aetion.com/leadership/carolyn-magill

With 3 consecutive days of $100M in funding, here is the most confusing (or rather the most confused we have been) Episode 147 of Health in 2 Point 00. Jess asks Matthew about Verily partnering with Swiss Re to get into the stop-loss insurance game, Prescryptive Health raising a $26M Series A for their maybe GoodRx-like or PBM platform, Sonde Health acquiring NeuroLex for its vocal biomarkers platform, Aetion reopening their Series B and raising another $19M to the $36M they have already raised, and Otsuka after investing millions of dollars in Proteus, deciding to buy the rest of it with $15M, but we don't know why any of these deals happened

In this week's episode, Carolyn Magill, CEO and board member for real-world analytics and evidence firm Aetion, speaks with MM&M's executive editor, Marc Iskowitz. She offers her perspective on how real world evidence (RWE) is finding its footing with pharma, including an update on its RCT Duplicate collaboration with the FDA, where she sees synthetic trials ultimately carving out a niche, and how to ensure that patient privacy needs are met.

Today's Guest: Carolyn Magill | CEO, Aetion Inc. Host Greg Matthews and Aetion CEO Carolyn Magill dive deep into the Real World Evidence - Why it's more important than ever for all the players in the health ecosystem to understand how to use it well. Important Links: Aetion: https://www.aetion.com/ Carolyn on Twitter: https://twitter.com/MagillOnHealth Carolyn on LinkedIn: https://www.linkedin.com/in/carolyn-magill-088246/ Scott Gottlieb joins Aetion board: https://www.fiercehealthcare.com/tech/former-fda-commissioner-scott-gottlieb-joins-health-startup-aetion-s-board-directors

We caught up with Carolyn Magill the CEO of Aetion at the #HLTH conference to capture some of her talk on the things smart companies do to close the gender gap. She shares pragmatic steps companies can take to address this pervasive problem in #healthcare and #healthIT. I hope you enjoy.

Do you have a half empty bottle of pills in your medicine cabinet that's just collecting dust? If so, you're not alone. In this episode of the Oliver Wyman Health Podcast, Tom Robinson, Partner in Oliver Wyman’s Health & Life Sciences practice, chats with Carolyn Magill, Aetion's Chief Executive Officer. Aetion is a digital health company turning real-world data into real-world decisions by examining how well clinical interventions work for different patient populations. Carolyn discusses her unique career trajectory from the world of nuclear weapons to the world of healthcare, and how Aetion is partnering with organizations and companies like The New England Journal of Medicine, McLean Hospital, Brigham and Women's Hospital, biopharma, payers, and more. For more information, follow us on Twitter @OWHealthEditor, read our online healthcare publication at health.oliverwyman.com, and see our guest roster: oliverwyman.com/oliverwymanhealthpodcast. Questions or comments? Email Oliver Wyman Health's Editor, jacqueline.dichiara@oliverwyman.com.

Our Host Steve Krupa has a visitor. Aetion CEO Carolyn Magill pops by Steve’s office at HealthEdge to explain how Aetion raised a round of capital it wasn’t seeking. She also delves deeply into how Aetion’s analysis of different types of data – genomic, socioeconomic, EHR’s – can change how healthcare is delivered and how are costs covered.You can WATCH this Breaking Health podcast interview here.

Sebastian Schneeweiss is Professor of Medicine and Epidemiology at Harvard Medical School and is one of the world’s leaders in analytic methods to understand the effectiveness of newly marketed medical products using healthcare databases. His research has been funded by NIH, PCORI, and FDA grants, and he’s also the co-founder of Aetion, a healthcare technology company that delivers the real-world evidence for value-based care.

In this episode of The Pulse Podcast, we interview Kristen Coletto, Strategic Partnerships at Aetion about using real world evidence to speed up drug R&D and recreate clinical trials with the FDA to make better decisions around drug approval and delivery. Aetion is a health care technology company that delivers real-world evidence to determine which treatments work best, for whom, and when.

In this talk, Junaid Kapadia, DevOps manager and staff software engineer for Aetion Systems, speaks about the company's journey from a Chef, Jenkins, and EC2-based architecture to a fault-tolerant, highly available, continuously provisioned, and deployed architecture via AWS CodePipeline, AWS CodeBuild, AWS CloudFormation, AWS Systems Manager Parameter Store, and Amazon Elastic Container Service (Amazon ECS). Kapadia also discusses the history of Aetion's original architecture, explains how it transitioned its movement to the new architecture, and shares specific caveats of the purpose of each service and why it was chosen. He also talks about future developments of the overall architecture.

Delivering real-world evidence to answer high-stake questions and discover the best treatment

In this dual podcast, we talk with leaders from the American Heart Association, Philips, UPMC, and Aphelion Capital about Cardeation Capital, a new venture fund aimed at funding start-ups in the digital health and medtech fields. How did the four entities join forces? What can they offer start-ups looking to disrupt healthcare? For more information go to aphelioncapital.net. You can also learn more about Aphelion Capital, the firm managing the fund, in this Medtech Talk Podcast. We also highlight one of its first investments, ExplORer Surgical in this Breaking Health Podcast.

Founder and CEO Joel Wishkovsky created Simple Contacts’ phone-based app to save contact lens wearers time and money when they need a new supply of lenses but not a new prescription. Ophthalmologists are funding the company and conducting the remote examinations. But the firm isn’t seen favorably by optometrists, who stand to lose a steady stream of business.

MedCrypt CEO Mike Kijewski is playing a long game. At the moment, he recognizes Medtech execs aren’t placing a high priority on cybersecurity of their devices. But as technology becomes more advanced – and hospitals grow more wary – he expects demand will grow. The time is coming for Medtech to take a cue from the iPhone, he says.

Verana Health, formerly known as DigiSight, is hoping to partner with clinical societies to build a deep cache of EHR data for pharma and medtech companies. The firm already is working with the American Academy of Ophthalmology, making its IRIS database available to commercial partners. Verana expects to create similar relationships with other clinical societies.

CareZone manages a mobile app that enables users to keep their medications, health information, and contacts all in one place. CEO Jonathan Schwartz shares the company’s origin (and early contact with PillPack, now an Amazon company).

In this week’s Breaking Health Podcast, Anita Pramoda, CEO of Owned Outcomes, digs deep into the joint venture between her company and Vizient Inc. Ediom, LLC, a cognitive computing and data science company solely focused on the needs of health care.

In this week’s Breaking Health Podcast, recently installed Aetion CEO Carolyn Magill visits with BH host Steve Krupa to share the value-based healthcare story that helped the company raise $36.4 million in a Series B from investors including New Enterprise Associates.

In this interview, co-founder, president, and chief scientific officer Jeremy A. Rassen discusses the company’s origins, technology, and impact on developing the data necessary to deliver value-based healthcare.